

# antr**ia**bio

*AntriaBio is a patient-centric biopharmaceutical growth company specializing in the development of innovative drug therapies for patients with diabetes and metabolic diseases*

- Headquarters located in Louisville, Colorado, U.S.A
- Approximately 45 employees
- Seasoned Management Team, Board of Directors & Scientific Advisory Board with extensive expertise developing and launching successful therapies
- Traded on OTCQB: ANTB
- Lead product candidate – **AB101** – is a once-weekly basal insulin for patients with type 1 and type 2 diabetes
  - ↳ Superior microsphere formulation of human insulin, PLGA and PEG
  - ↳ Compelling in vivo data, including repeat dosing, in three animal species: rats, dogs and diabetic mini-pigs
  - ↳ IND to be filed with FDA in June 2017
  - ↳ First-in-human Phase 1 clinical study will assess safety, pharmacokinetics & pharmacology of sequential single doses of AB101 in patients with diabetes
  - ↳ Phase 1 study to be conducted with Prosciento (formerly known as the Profil Institute for Clinical Research)
  - ↳ Interim data readout expected prior to end of year 2017
  - ↳ Potential first-in-class and best-in-class once-weekly insulin to compete in >\$10 Billion basal insulin market

# *antria*bio

---

*AntriaBio is a patient-centric biopharmaceutical growth company specializing in the development of innovative drug therapies for patients with diabetes and metabolic diseases*

---

- **AB301** – is a once-weekly injectable combination of a PEGylated human GLP-1 agonist and PEGylated insulin for patients with type 2 diabetes
  - ↳ AB301 drug substance utilizes native human GLP-1 with no substitutions or deletions
  - ↳ Currently conducting in vivo studies in normal and diabetic rodent models
  - ↳ Combination therapy has potential to complement glycemic control while attenuating weight gain and hypoglycemic risk
- Actively conducting animal studies to screen additional potential product candidates to further evolve drug pipeline